The current prospective study revealed that women receiving adjuvant chemotherapy for breast cancer who had an initial AMH level greater than 1.475 ng/mL could be significantly less likely to develop CIA than those with levels lower than 1.475 ng/mL. The gene discussed is AMH; the disease is breast cancer.